Quick Answer
AIM ImmunoTech Inc. reported Revenue (ASC 606) of $88.0 thousand for fiscal year 2025.
AIM ImmunoTech Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $88.0K | -48.2% |
| 2024 | $170.0K | -15.8% |
| 2023 | $202.0K | +43.3% |
| 2022 | $141.0K | +4.4% |
| 2021 | $135.0K | -17.2% |
| 2020 | $163.0K | +16.4% |
| 2019 | $140.0K | -61.9% |
| 2018 | $367.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $26.0K | -25.7% | +4.0% |
| June 30, 2025 | $25.0K | -50.0% | +56.2% |
| March 31, 2025 | $16.0K | -60.0% | -54.3% |
| September 30, 2024 | $35.0K | -23.9% | -30.0% |
| June 30, 2024 | $50.0K | +19.0% | +25.0% |
| March 31, 2024 | $40.0K | -18.4% | -13.0% |
| September 30, 2023 | $46.0K | +119.0% | +9.5% |
| June 30, 2023 | $42.0K | +40.0% | -14.3% |
- AIM ImmunoTech Inc. showed a decrease of -48.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2025 period, AIM ImmunoTech Inc.’s revenue (asc 606) has declined by 76.0% (from $367.0 thousand to $88.0 thousand).
- The most recent figure is from AIM ImmunoTech Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: